The new generation of molecular urological diagnostics
The oncology diagnostics market is evolving towards non-invasive, more precise and scalable molecular solutions adapted to personalized medicine.
Molecular diagnostics
Personalized medicine
Scalable platform
Urine miRNA biomarkers analyzed through high-sensitivity RT-qPCR technology.
Tools designed to support clinical and therapeutic decision-making.
Technology adaptable to hospitals, laboratories and international diagnostic networks.
>90%
33%
Non-invasive
$9.2B
Clinical precision
Lower cost
Urine sample
Market opportunity
An unmet medical and economic need
Bladder cancer has a high recurrence rate and requires long-term monitoring, creating a significant burden for patients, hospitals and healthcare systems.
+550,000
+70%
€150,000
annual global cases
recurrence rate
cost per patient
A significant global market with recurring needs for diagnosis and monitoring.
High recurrence multiplies the volume of follow-up procedures and accumulated costs.
One of the oncology indications with the highest accumulated economic burden.
The result: healthcare systems under pressure, saturated hospitals and a clear opportunity for non-invasive, precise and cost-effective molecular alternatives.
PROPRIETARY TECHNOLOGY
BlaDimiR Platform
Danae Urogenomics is developing a family of urine-based miRNA biomarker solutions with applications in diagnosis, monitoring and therapy response prediction.
Non-invasive diagnosis and monitoring of bladder cancer
Urine-based miRNA biomarkers
High sensitivity and specificity
Designed for clinical practice
Therapy response prediction
Advanced assessment of combination therapies
Supports clinical decision-making
Personalized medicine approach
Value for hospitals and networks
miRNAs + cytokines
Complex clinical contexts
Pipeline scalability
COMPETITIVE ADVANTAGE
Strategic differentiators
BlaDimiR combines molecular precision, lower cost, operational scalability and intellectual property protection in a platform with international expansion potential.
Superior precision
A simple molecular alternative designed to reduce reliance on invasive procedures.
Strong patents
Lower cost
BlaDimiRPLUS + BlaDimiRIO
Clinical precision based on urine miRNA biomarkers.
Non-invasive test
33%
Lower cost than competing solutions, improving adoption potential.
Proprietary pipeline
>90%
Expansion toward therapy response prediction and personalized medicine.
Intellectual property
Urine sample
Technology protected in key markets, supported by scientific evidence and international publications.
A differentiated platform designed to transform bladder cancer diagnosis, monitoring and therapeutic stratification.
SCALABLE MODEL
An asset-light model built for licensing, CDx and global scale
Danae Urogenomics concentrates value in intellectual property, clinical evidence, regulatory certification and strategic partnerships. Its model is designed to scale the BlaDimiR platform through ISO 13485-based services, technology transfer, international licensing and CDx collaborations, without relying on an intensive industrial or commercial structure.
ISO 13485 clinical services
Technology transfer & licensing
Companion Diagnostics CDx
International scale-up through agreements with IVD manufacturers, licensed laboratories and diagnostic partners with regulatory, commercial and industrial capabilities.
Multicenter clinical validation
Evidence generation and real-world data
Pilot agreements with hospitals and laboratories
Initial model focused on clinical validation, evidence generation and diagnostic service delivery in collaboration with hospitals and specialized laboratories.
Therapy response prediction
Pharma and immuno-oncology collaborations
Service fees, upfronts and royalties per test/patient
Development of BlaDimiRplus and BlaDimiRIO as predictive tools for personalized medicine, immuno-oncology and patient selection in collaboration with pharmaceutical companies.
Technology transfer to CE/FDA partners
Upfronts, milestones and royalties
Global expansion without own industrial infrastructure
8%
IP royalty rate
>30M€
Projected 2035 revenue
>85%
Potential model margin
ROADMAP
From clinical validation to international scale-up
Danae Urogenomics is advancing through a progressive strategy to clinically validate BlaDimiR, obtain regulatory certification and scale adoption across hospitals, laboratories, insurers and international partners.
2025 - 2026
2026 - 2027
2027 - 2028
2029 - 2030
Clinical validation
Certification and initial adoption
European expansion
Global licensing
Multicenter clinical studies and first pilot hospitals in Spain.
CE-IVD process launch, clinical evidence generation and first commercial sales.
Entry into key European markets and agreements with distributors and laboratories.
Strategic agreements with diagnostics companies and expansion towards the U.S. market.
TRACTION AND VALIDATION
Validated, protected and scientifically backed technology
Danae Urogenomics combines intellectual property, scientific publications, ongoing clinical validation and institutional support to advance BlaDimiR toward clinical and commercial adoption.
Intellectual property
Granted patent and international protection
Spanish patent granted, PCT application advanced in Europe and the U.S., and protection strategy focused on key markets.
Scientific evidence
Publications in specialized journals
Published results in peer-reviewed scientific journals support the robustness of urine-based miRNA biomarkers.
Clinical validation
Multicenter study underway
Clinical validation designed to support BlaDimiR integration into hospital and laboratory environments.
Support and adoption
Grants, hospitals and early contacts
Competitive institutional support, collaboration with reference hospitals and first steps toward commercial agreements.
A strong scientific, clinical and regulatory foundation to accelerate the commercial and international adoption of BlaDimiR.
Let’s build the next generation of urological diagnostics together
STRATEGIC PARTNERSHIPS
Danae Urogenomics offers a science-backed molecular platform with international scale-up potential and applications in diagnosis, monitoring and personalized medicine. We are seeking strategic partners to accelerate clinical and commercial adoption.
Validated and protected technology
Scalable model with recurring revenue
Licensing and strategic collaboration opportunities
Request information for investors and partners
Our team will contact you to provide further information about the BlaDimiR platform, partnership opportunities, licensing or strategic investment.
Molecular diagnostics for bladder cancer based on urine miRNA biomarkers.
BlaDimiR by Danae Urogenomics
Platform
Opportunities
Contact
© 2026 Danae Urogenomics. All rights reserved.